Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | CFB | P00751 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556631 | 1.00 | AHR (0.48) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL31488003 | 0.81 | AHR (0.42) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL265821 | 0.81 | AHR (0.42) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL31146936 | 0.81 | AHR (0.42) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL265955 | 0.81 | AHR (0.42) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL25407907 | 0.81 | DRD4 (0.39) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL2767894 | 0.81 | DRD4 (0.41) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL620047 | 0.81 | TNF (0.39) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL2768928 | 0.81 | DRD4 (0.39) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL3068349 | 0.81 | AHR (0.42) | AHRPRKCIPARP1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250063947-A1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC DEVICES | HELIATEK GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| EP-4024489-B1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC COMPONENTS | HELIATEK GMBH (DE) | 2023-10-04 | — | — | EP | disclosed |
| EP-4024489-B1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC COMPONENTS | HELIATEK GMBH (DE) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023126486-A1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC DEVICES | HELIATEK GMBH (DE) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023126486-A1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC DEVICES | HELIATEK GMBH (DE) | 2023-07-06 | — | — | WO | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-11623921-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-11 | — | — | US | disclosed |
| EP-4024489-A1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC COMPONENTS | Heliatek GmbH (DE) | 2022-07-06 | — | — | EP | disclosed |
| EP-4024489-A1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC COMPONENTS | Heliatek GmbH (DE) | 2022-07-06 | — | — | EP | disclosed |
| EP-2443111-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2012021591-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2010145203-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010145203-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | UNIVERSITE JOSEPH FOURIER (FR) | 2010-06-10 | — | — | US | disclosed |
| CN-101652346-A | Novel indole derivatives, process for their preparation and their use, especially as antibacterial agents | UNIV JOSEPH FOURIER FR | 2010-02-17 | — | — | CN | disclosed |
| EP-2121601-A2 | NOVEL INDOLE DERIVATIVES, METHODS FOR PREPARING SAME, AND USE THEREOF PARTICULARLY AS ANTIBACTERIAL AGENTS | Université Joseph Fourier (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008110690-A2 | NOVEL INDOLE DERIVATIVES, METHODS FOR PREPARING SAME, AND USE THEREOF PARTICULARLY AS ANTIBACTERIAL AGENTS | UNIVERSITE JOSEPH FOURIER (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | AHR 1570/4885PRKCI 531/4885PARP1 542/4885 |
| US-11623921-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | AHR 1570/4885PRKCI 531/4885PARP1 542/4885 |
| US-20250063947-A1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC DEVICES | CYP2C19, CYP2C9, CYP2E1 | AHR 1598/4885PRKCI 4487/4885PARP1 3132/4885 |
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | GPBAR1, TPH1, GPER1 | AHR 354/4885PRKCI 2826/4885PARP1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.